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994Immunophenotyping of Stage III Melanoma
Reveals Parameters Associated with
Patient Prognosis
Nicolas Jacquelot1,2,3,25, Marı´a Paula Roberti1,3,4,25, David P. Enot3,5,25, Sylvie Rusakiewicz1,3,4,
Michaela Semeraro1,3,6, Sarah Je´gou7, Camila Flores3, Lieping Chen8, Byoung S. Kwon9,10,
Christophe Borg11,12,13, Benjamin Weide14, Franc¸ois Aubin15, Ste´phane Dalle16, Holbrook Kohrt17,
Maha Ayyoub1,2,3,4, Guido Kroemer3,5,18,19,20,21,22, Aure´lien Marabelle1,3,4, Andre´a Cavalcanti3,23,24,
Alexander Eggermont3,25 and Laurence Zitvogel1,2,3,4,25Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic
factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph
node invasion and the BRAFV600 activating mutation have clinical significance. Based on a comprehensive
immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in
39 metastatic melanomas, we found that blood markers were as contributive as tumor-infiltrated lymphocyte
immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical
significance than those related to activation or lineage. High frequencies of CD45RAþCD4þ and CD3eCD56e
tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival.
High NKG2D expression on CD8þtumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated
lymphocytes, and low PD-L1 expression on circulating T cells were retained in the multivariate Cox analysis
model to predict prolonged overall survival. Prospective studies are needed to determine whether such
immunological markers may guide adjuvant therapies in stage III metastatic melanomas.
Journal of Investigative Dermatology (2016) 136, 994e1001; doi:10.1016/j.jid.2015.12.042INTRODUCTION
Cutaneous melanoma is the major cause of mortality among
skin malignancies (Eggermont et al., 2014). The prognostic
factors for primary melanomas are Breslow thickness, ulcer-
ation, and mitotic index (Balch et al., 2009; Thompson et al.,
2011). In stage III melanoma, the major prognostic factors
are microscopic versus palpable nodal disease, number of
positive nodes, and ulceration of the primary lesion (Balch
et al., 2010). In stage IV melanoma, skin/subcutaneous
tissue metastases and low serum levels of lactate dehydro-
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(Balch et al., 2009). In the pioneering study of Erdag
et al. (2012), higher counts of CD45þ, CD138þ, CD20þ,
CD3þ, CD8þ, and PD-1þ tumor-infiltrated lymphocytes
(TILs; assessed by comprehensive immunohistochemistry
analyses of stage IV metastatic melanoma [MM] lesions) were
all independently associated with better survival after
adjusting for key clinical covariates, whereas abundances of
CD4þ T cells, regulatory T cells (Tregs), natural killer (NK)
lymphocytes, mature dendritic cells, or macrophages were
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Immune Prognostic Factors in Stage III MelanomasThe understanding of genetic heterogeneity of MM has
revolutionized its clinical management. The discovery that
40e45% of melanomas harbor BRAF activating mutations,
mostly at codon V600, launched a burst of targeted therapies
involving BRAF and then MEK inhibitors (Chapman et al.,
2011; Hauschild et al., 2012). Apart from cell autonomous
effects associated with blocking oncogene addiction, BRAF
inhibitors mediate their bioactivity on tumor-host interaction
by inhibiting suppressive cytokines (such as IL-10, IL-6,
vascular endothelial growth factor) (Sumimoto et al., 2006),
reinstating dendritic cell function (Ott et al., 2013),
increasing melanoma antigen presentation (Frederick et al.,
2013), and T-cell activation (Boni et al., 2010; Frederick
et al., 2013), leading to increased clonality of TILs (Cooper
et al., 2013). However, distinct hallmarks of resistance to
adaptive immunity occur after BRAF inhibition, such as MEK-
and PI3K-dependent PD-L1 expression on tumor cells
(Frederick et al., 2013; Jiang et al., 2013). PD-L1 up-regula-
tion has been associated with high TIL content and IFN-
geproducing TILs (Kluger et al., 2015; Taube et al., 2012),
but contradictory results about PD-L1 expression and prog-
nosis of MM have been reported (Kluger et al., 2015; Massi
et al., 2015). Indeed, CD8þ T cells recognizing melanoma
antigens eventually express exhaustion markers such as
PD-1, the receptor for PD-L1, and/or CTLA-4, Tim-3, Lag3,
KIR, and other immune checkpoints, thereby exhibiting
impaired IFN-g and IL-2 secretion (Ahmadzadeh et al., 2009;
Baitsch et al., 2011). Hence, immunotherapy of MM has
come of age with the recent success of immune checkpoint
blockers (Eggermont et al., 2015). A number of studies have
shown the prognostic impact of cytotoxic or Tregs circulating
in the blood or residing in primary or metastatic lesions (Oble
et al., 2009). A few studies performed in sentinel lymph
nodes using immunohistochemistry, gene profiling, or
flow cytometry described several mechanisms of immune
subversion on melanoma antigen-specific T cells (Straten
et al., 2006), such as Tregs (Mohos et al., 2013), distinct
dendritic cell subtypes (Elliott et al., 2007), and specific
receptors (Vallacchi et al., 2014). Because these results were
controversial (Camisaschi et al., 2014), we undertook a
comprehensive immunophenotyping of paired blood and
metastatic lymph nodes (mLN) including 252 immune pa-
rameters (lineage-, activation-, exhaustion-related markers) to
harness the most robust immune profiles endowed with
clinical significance for progression-free survival (PFS) or
overall survival (OS). Here we describe immunotypes corre-
sponding to specific clinical traits as well as blood or
tumor parameters associated with PFS and OS. These
immunophenotypes should be validated prospectively and
may guide future studies using immune checkpoint blockers
or immunomodulators.
RESULTS AND DISCUSSION
Immunotypes associated with lymph node
invasion and BRAFV600 mutation
The patient cohort consisting of 39 MMs that benefited from
surgery for mLN is described in Supplementary Table S1
(online), with their survival curves shown in Supplementary
Figure S1 (online). Immediately after mechanical and enzy-
matic digestion of mLN, tumor and blood compositions wereanalyzed in a paired manner for 25 patients by flow cytom-
etry (antibodies listed in Supplementary Table S2 online),
with the gating strategy exemplified in Supplementary
Figure S2 (online). Of the 337 parameters initially selected,
252 were found to be robustly quantified, with 124 and 128
in blood and tumor, respectively. They reflect multiple
cellular types, activation status, naı¨ve or memory pheno-
types, and activating or inhibitory receptors and ligands. The
markers are shown in the form of dependency networks in
Supplementary Figures S3 and S4 (online), which illustrate
the complexity of the immune tone. However, no reliable
clustering of markers could be found.
Briefly, mLN contained about 27% CD45þ live cells
(see Supplementary Figure S5a online), enriched in CD3þ
T cells compared to blood (see Supplementary Figure S5b),
more specifically CD4þ T cells (see Supplementary
Figure S5c). NK cells were underrepresented in tumor beds
(see Supplementary Figure S5d), as previously observed
(Messaoudene et al., 2014). About 41%of CD4þ TILs and 54%
of CD8þ TILs (cytotoxic T lymphocytes [CTLs]) produced IFN-
g (>2%) and proliferated (Ki67þ cells), whereas about 90% of
TILs secreted tumor necrosis factor-a (>2%) after ex vivo
stimulation (see Supplementary Figure S5e).Most of theseCTLs
were highly activated as assessed byCD69 (see Supplementary
Figure S6a online), as described for hepatocellular carcinoma
(Chen et al., 2007) and CD27, CD137, CD95, and CD137L
expression levels (see Supplementary Figure S6bee). Expres-
sion of inhibitory receptors (such as PD-1, Tim-3) and their
ligand PD-L1 on T and NK cells is shown in Supplementary
Figure S6fei. In accordance with previous reports (Tumeh
et al., 2014), PD-L1 expression on intratumoral as well as
blood T cells was not insignificant.
We next investigated immunological traits associated with
classic prognostic parameters of melanoma. Significant
markers are all summarized in Supplementary Tables S3 and
S4 (online) (blood- and tumor-related markers, respectively,
arbitrarily setting the threshold of significance at a raw
P-value of 0.05).
The number of invaded LN (>3Nþ) was associated with a
dismal prognosis in these stage III MMs (see Supplementary
Figure S7a online). We observed a drop in circulating
CD4þ T cells (Figure 1a), whereas CD4þ T cells increased in
tumor (compared with poorly disseminated diseases; see
Supplementary Figure S7b). Highly invaded LN contained
few PD-1þCD8þ T cells (Figure 1b), a trait associated with a
lower PD-1þTim-3þCD8þ/Treg ratio (see Supplementary
Figure S7c), and the CD8þ/Treg ratio was correlated with
CTLs (see Supplementary Figure S7d). Additionally,
CD3eCD56e cells comprising B cells and major histocom-
patibility complex class IIlow myeloid cells of granulocytic
origin (see Supplementary Figure S8 online) lost CD137L
expression cells in both compartments in heavily invaded LN
(Figure 1c and Supplementary Figure S7e). In accordance
with our data, CD137L-expressing B cells are known to
represent an evolutionary conserved subset of memory B
cells with antimetastatic properties that accumulates in the
elderly and correlates with granzyme Bþ CD8þ T cells (Lee-
Chang et al., 2014). Moreover, activation markers on NK
cells, already reported as being associated with functional
activity and prognosis (Ali et al., 2014), decreased withwww.jidonline.org 995
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Figure 1. Immunotypes associated
with the BRAFV600 mutation and the
severity of lymph node invasion. Drop
in (a) circulating CD4þ and (b)
intratumoral CD8þPD-1þ T-cell
proportions according to metastatic
lymph node invasion. (c) Distribution
in blood of CD137LþCD3eCD56e
cells according to the number of
invaded lymph nodes. Decreased
CD137L expression in distinct
circulating leukocyte subset in
patients harboring BRAFV600 mutated
tumors. (d, e) Flow cytometric
analyses of blood leukocytes assessing
CD137L expression on (d) CD8þ or
(e) NK cells. (f) Increased percentages
of CD45RAþCD4þ T cells in tumor-
infiltrated lymphocytes from mutated
tumors as assessed by flow cytometry.
Each dot represents one patient.
Wilcoxon Rank-Sum test: all P-values
are indicated.
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996mLN invasion, in particular PD-L1 and CD137L (see
Supplementary Figure S7f). All of these data suggest that once
tumor cells operate an exodus from lymph nodes, dissemi-
nation of the disease might induce a coordinated dysfunction
of several components of the immune system concomitantly.
The BRAFV600 oncogenic mutation was an independent
prognosis factor associated with shorter OS (see
Supplementary Figure S9a online). The immunological hall-
marks associated with the activating BRAFV600 mutation were
a drop in blood CD137L- and PD-L1eexpressing CD8þ
T cells (Figure 1d and Supplementary Figure S9b) and a
profound decrease in CD137Lþ circulating NK cells
(Figure 1e). In addition, the CD4þ T-cell compartment in
tumor beds was altered with a trend toward an increase of
naı¨ve CD45RAþCD4þ T cells (Figure 1f) and a drop in Lag3-
expressing Tregs (see Supplementary Figure S9c).
Stage III MMs contain CD45RADCD4D TILs and Treg
inversely correlating with intratumoral CTLs and OS
At the expense of CD4þ T cells, intratumoral accumulation
of CTLs in mLN are known to be of favorable prognosis in MM
(Bogunovic et al., 2009; Mihm et al., 1996; Oble et al., 2009).
AmongCD4þTILs, a large proportionswereCD45RAþCD4þT
cells, with about 83% of naı¨ve CD45RAþCCR7þcells (not
shown) that anticorrelated with CTLs and PD1þCD8þ TILs
(Figure 2aec). When classifying our 252 immunological
markers determined in blood and tumor beds according to
their clinical significance in stage IIIeIV MM, we concluded
that high proportions of naive CD45RAþCD4þ TILs were
associated with rapid disease progression (Figure 2d) andJournal of Investigative Dermatology (2016), Volume 136remained significant after adjusting for mLN invasion, there-
fore adding prognostic value to local aggressiveness (hazard
ratio ¼ 4.3 and 3.1, respectively).
Besides naı¨ve T cells, the CD4þ TIL fraction contained a
high proportion of CD25highCD127eCD4þ Tregs (Figure 3a),
which correlated with the activation status of CD4þ and
CD8þ T cells (CD69 and PD-1/TIM3 expression, respectively;
Figure 3b and c). When stratifying on the BRAF mutational
status, we observed that the proportions of Treg TILs dictated
OS, with the worse subgroup of patients being those
harboring a BRAFV600 MM and high percentages of Treg
(above the median; Figure 3d).
Tumoral NKG2D and blood PDL-1 expression on CD8D
T cells influence OS in stage III MM
NKG2D is an important activating receptor associated with
cytolytic functions of CTL and NK cells (Diefenbach et al.,
2001). NKG2D engagement is dictated by the presence of
their major histocompatibility complex class I- like ligands
expressed by tumor cells (mainly MICA/B and ULBP2 in
melanoma) (Paschen et al., 2009). Tumor-associated metal-
loproteinases induce ligand release, NKG2D engagement,
and functional defects (Paschen et al., 2009; Waldhauer and
Steinle, 2006). In contrast to stage IV MM (Romero et al.,
2014), stage III melanoma maintained high expressions of
NKG2D receptors in blood (Figure 4a and data not shown),
but such expressions decreased in tumor beds in many
patients, a trait relevant for OS (hazard ratio ¼ 0.15
after adjusting for most significant covariates). When com-
bined with BRAF mutation, very high percentages of
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Figure 2. Naı¨ve CD45RADCD4D T
cells inversely correlated with
intratumoral cytotoxic T lymphocytes
and were associated with shorter
progression-free survival (PFS).
(a) Flow cytometric analyses of
blood leukocytes and tumor-infiltrated
lymphocytes (TILs) assessing the
lineage-related marker CD45RA in
CD4þ T cells in a paired manner.
(b, c) Spearman correlations between
the percentages of CD4þCD45RAþ
TILs and CD8þ cytotoxic T
lymphocytes or PD1þCD8þ TILs. Each
dot represents one patient. Wilcoxon
paired signed-rank and Spearman
correlation tests: P-values are
indicated. (d) Kaplan-Meier PFS
curves segregating the cohort of
metastatic melanoma patients
according to the median value of
CD4þCD45RAþ TILs retained in the
Cox multivariate model in tumor
analyses. Likelihood ratio tests from
Cox regression modeling are used to
assess the prognostic value for the
marker with and without accounting
for metastatic lymph node (mLN)
invasion status (0e3 vs >3).
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Immune Prognostic Factors in Stage III MelanomasNKG2DþCD8þ TILs protected against the BRAF mutation-
associated dismal prognosis (Figure 4b). With the exception
of two, all patients presenting a BRAF mutation but high
NKG2D expression on CD8þ TILs survived >2 years.
The expression of inhibitory receptors (PD-1, TIM3,
CTLA-4) was higher in TILs than blood cells and more in
CD8þ than CD4þ TILs, except for CTLA-4 expression (see
Supplementary Figure S6f and g and data not shown). In
contrast, PD-L1, the ligand for PD-1, was equally expressed
in almost all leukocyte subsets in blood and tumor beds (see
Supplementary Figure S6h and Figure 4c, upper panel).
Interestingly, the mean fluorescence intensity of PD-L1
expression (compared with that of the isotype control anti-
body) on the surface of circulating CD8þ T cells (or CD4þ T
cells; see Supplementary Figure S10a online) correlated with
the percentages of PD-L1þCD8þ T cells (Figure 4c, lower
panel) and PD-L1þCD4þ T cells (see Supplementary
Figure S10b). In accordance with Chevolet et al. (2015),
high expression levels of PD-L1 on CD4þ and CD8þ T
lymphocytes were associated with a bad prognosis, even
more so in the presence of the BRAF paradigmatic mutation
(Figure 4d and Supplementary Figure S10c). PD-L1 is
expressed on a subset of melanoma, most likely as a
consequence of lymphocytic infiltrates, in particular IFN-
geproducing CTLs (Massi et al., 2015; Taube et al., 2012).
However, PD-L1 can also be expressed by immune cells at
similar levels as in tumor cells and equally well in blood and
tumor compartments, in a coordinated manner in all cell
types (CD4þ T, CD8þ T, NK, CD45e, CD3eCD56e; see
Supplementary Figures S3, S4, and S6). Chevolet et al. (2015)
reported an interconnected overexpression of IDO, PD-L1,and CTLA-4 in peripheral blood leukocytes in MM, associ-
ated with advanced disease and negative clinical outcome.
High levels of circulating PD-L1eexpressing CTLs and
CTLA-4eexpressing Treg conferred a negative prognosis.
Dismal prognosis role for non-T cells and non-NK
cells in the tumor of stage III MM
CD3eCD56e cells, comprising B cells and major histocom-
patibility complex class IIlow myeloid cells of granulocytic
origin (see Supplementary Figure S8), were not increased in
the tumor microenvironment (Figure 5a). However, their
blood phenotype was modified by the presence of tumor cells
at a distant site in that they lost their CD137L expression in
cases of heavily invaded stage III MM (Figure 1c). Supporting
their regulatory role, their proportions are negatively and
positively correlated with the favorable CTL TILs and the bad
prognosis CD4þCD45RAþ TIL subset, respectively (Figure 5b
and c). High intratumoral CD3eCD56e cells were associated
with short PFS, even in cases of poorly invaded LN
(Figure 5d).
Overall, when classifying our 252 immunological markers
determined in blood and tumor beds according to their
biological (lineage vs. activation vs. exhaustion; see
Supplementary Tables S3 and S4) and clinical significance
(>3Nþ, capsular rupture, BRAF mutational status, ulceration
status, and gender; see Supplementary Figure S11 online) in
stage IIIeIV MM, we concluded that (i) both blood and tumor
markers equally contributed to defining the prognosis,
(ii) exhaustion markers markedly affected the clinical
outcome, and (iii) activation markers appeared less relevant
for the functional study of tumor beds (see Supplementarywww.jidonline.org 997
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Figure 3. Regulatory T-cell (Treg)
tumor-infiltrating lymphocytes (TILs)
negatively impact on overall survival
(OS) and overrule BRAF mutational
status. (a) Flow cytometric analyses
of blood leukocytes and tumor
infiltrating cells assessing the
CD127eCD25high cells in CD4þ TILs
(Treg) in a paired manner. (b, c)
Spearman correlations between the
percentages of Treg and (b)
CD4þCD69þ TILs and (c)
CD8þPD1þTIM3þ TILs. Each dot
represents one patient. Wilcoxon
paired signed-rank and Spearman
correlation tests: P-values are
indicated. (d) Kaplan-Meier OS curves
segregating the cohort of metastatic
melanoma patients according to the
median value of Treg TILs retained in
the Cox multivariate model in tumor
analyses. Likelihood ratio tests from
Cox regression modeling are used to
assess the prognostic value for the
marker with and without accounting
for BRAF mutational status (mutated
[M] vs wild type [WT]).
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998Figure S12 online). In our panels, we found (arbitrarily setting
the threshold of significance at a raw P-value of 0.05),
that only a few markers (just six) may represent prognostic
factors influencing PFS or OS in blood or tumor beds inde-
pendently of clinicopathological parameters in multivariate
Cox regression analyses. Of note, specimen sampling after
neoadjuvant therapy did not influence these results.
Altogether, all the modulations of the components of natural
immunosurveillance against stage III MM described in this
study deserve to be validated prospectively in order to be
followed in the course of the development of monoclonal
antibody therapies.
MATERIALS AND METHODS
Patient characteristics
For the Gustave Roussy Cancer Campus cohort, patients >18 years
old with histologically confirmed metastatic and/or resectable mel-
anoma provided written informed consent according to protocols
reviewed and approved by the institutional ethic committee,
including the investigator-sponsored MSN study (NCT02105168).
For the Centre Hospitalier Lyon Sud cohort, patients >18 years old
with histologically confirmed metastatic and/or resectable (for all
stage III) melanoma were included in the study. All patients provided
informed consent before enrollment. Patient characteristics are
described in Supplementary Table S1.
Peripheral blood mononuclear cell preparations
Peripheral blood samples from patients drawn just before surgery
were carefully layered on top of a Ficoll-Hypaque density gradient
media (PAA Laboratories, Coelbe, Germany). For all relevant
parameters described in this study, the neoadjuvant treatment
administered before blood and tumor sampling did not significantlyJournal of Investigative Dermatology (2016), Volume 136impact on the results (see Supplementary Table S1 and data not
shown).
TIL preparations
Resected mLN specimens from MM patients were placed in isotonic
solution at least for 1 hour. These media (secretome) were frozen until
protein dosage. Next, tissue was cut and placed in dissociation me-
dium,whichconsistedofRPMI1640,1%penicillin/streptomycin (PEST,
Gibco Invitrogen, Grand Island, NY), collagenase IV (50 IU/ml), hyal-
uronidase (280 IU/ml), andDNAse I (30 IU/ml) (all fromSigma-Aldrich,
St. Louis, MO), and run on a gentleMACS dissociator (Miltenyi Biotec,
Bergisch Gladbach, Germany). Dissociation time lasted 1 hour under
mechanical rotation and did not influence the results of the pheno-
typing. Cell samples were diluted in phosphate buffered saline, passed
through a cell strainer, and centrifuged for 5 minutes at 1,500 r.p.m.
Cells were finally resuspended in phosphate buffered saline, counted,
stained for flow cytometric analyses, or resuspended in CryoMaxx
medium (PAA Laboratories) for storage in liquid nitrogen. All mLNs
included in the study were histologically confirmed to be invaded.
Flow cytometric analyses
For membranous labeling, peripheral blood mononuclear cells
and TILs were stained with fluorochrome-coupled monoclonal an-
tibodies (detailed in Supplementary Table S2), incubated for 20
minutes at 4 C, and washed. Some dissociated cells from mLNs
were incubated in 48-multiwell dishes at 0.3  106 leukocytes per
milliliter. After 18e24 hours of cell recovery cultured in complete
medium (RPMI1640 supplemented with 10% human AB serum, 1%
penicillin/streptomycin [PEST, Gibco Invitrogen], 1% L-glutamine
[Gibco Invitrogen], and 1% sodium pyruvate [Gibco Invitrogen]),
some of these cells were stimulated with phorbol 12-myristate
13-acetate (5 ng/ml; Sigma), ionomycin (125 ng/ml; Sigma), and
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Figure 4. NKG2D and PDL-1
expression on CD8D tumor-
infiltrated lymphocytes and blood
cells influenced the prognosis of stage
III metastatic melanoma. (a). Flow
cytometric analyses of CD8þ T cells
for NKG2D expression and (b)
prognosis value shown by Kaplan-
Meier overall survival (OS) curves
segregating the cohort of metastatic
melanoma patients according to the
median value of CD8þNKG2Dþ
tumor-infiltrated lymphocytes and
BRAF mutational status (mutated [M]
vs wild type [WT]) both retained in the
Cox multivariate model. (c) Mean
fluorescence intensity (MFI) of
membrane expression of PD-L1 on
CD8þ blood T cells compared with
the isotype control antibody MFI (ratio
of MFI, upper panel) and its Spearman
correlation with the percentages of
circulating PD-L1þCD8þ T cells
(lower panel). Wilcoxon paired
signed-rank and Spearman correlation
tests: P-values are indicated. (d) Same
as b but using the MFI ratio of PD-L1
positivity on CD8þ cytotoxic T
lymphocytes for the Kaplan-Meier
curve of OS.
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Immune Prognostic Factors in Stage III MelanomasBD Golgi Stop (4 ml/6 ml; BD Biosciences, San Jose, CA) during 3e5
hours and then harvested, membranous labeled to discriminate
different lymphocyte subsets (see Supplementary Table S2), and
permeabilized with BD Cytofix/Cytoperm kit (BD Biosciences).
Intracellular staining was performed with antieIFN-gePE (clone
B27; BD Biosciences) and anti-tumor necrosis factorea-AF647
(clone Mab11; BioLegend, San Diego, CA) antibodies following the
manufacturer’s protocol. For Ki67 staining, other cells was cultured
for 4e5 days before assessment of proliferation status. Briefly, cells
were harvested, membranous labeled, permeabilized with Foxp3/
transcription factor fixation/permeabilization kit (eBiosciences, San
Diego, CA), and intranuclear stained with antieKi67-PE (clone B56;
BD Biosciences, San Diego, CA) antibody following the manufac-
turer’s recommendations. Cell samples were acquired on a Cyan
ADP 9-color flow cytometer (Beckman Coulter, Marseille, France)
with single-stained antibody-capturing beads used for compensation
(Compbeads, BD Biosciences). Data were analyzed with Flowjo
software version 7.6.2 (Tree Star, Ashland, OR).
Cytokines and chemokines measurements
Tumor-conditioned supernatants were monitored using the
human Th1/Th2/Th9/Th17/Th22 13-plex RTU FlowCytomix Kit(eBiosciences) and the human Chemokine 6 plex kit FlowCytomix
(eBiosciences) according to the manufacturer’s instructions and
acquired on a Cyan ADP 9-color flow cytometer (Beckman Coulter).
Analyses were performed by Flowcytomix Pro 3.0 Software (eBio-
sciences). CXCL10 (BD Biosciences) was measured by ELISA kit in
accordance with the manufacturer’s recommendations. All cyto-
kines/chemokines were normalized to the total protein content as
measured by the DC protein assay (Bio-Rad, Hercules, CA) following
the manufacturer’s protocol.
Statistical analysis
Data analyses and representationswere performedwith either Prism 5
(GraphPad, San Diego, CA) or within the statistical environment R
(http://www.R-project.org/). In total, 124 (blood) and 128 (tumor)
parameterswere considered for analyses and reporting. Spearman test
was applied to assess correlations between parameters (Prism 5). All
remaining calculations were performed within R. Individual data-
points representing the measurement from one patient are systemati-
cally graphed alongside with the box and whisker plots calculated
from the corresponding distribution. Comparisons between clinical
groupswere performed by beta regression for parameters expressed in
percentage and by linear modeling for the other parameters and ratioswww.jidonline.org 999
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Figure 5. Tumor CD3eCD56e
cells inversely correlated with
intratumoral cytotoxic T lymphocytes
(CTLs) and negatively predicted
progression-free survival (PFS). (a)
Flow cytometric analyses of blood and
tumor CD3eCD56e cells performed in
a paired manner. (b, c) Spearman
correlations between CD3eCD56e
cells and (b) CD8þ CTL tumor-
infiltrated lymphocytes and (c)
CD4þCD45RAþ tumor-infiltrated
lymphocytes. Each dot represents one
patient. Wilcoxon paired signed-rank
and Spearman correlation tests: P-
values are indicated. (d) Kaplan-Meier
PFS curves segregating the cohort of
metastatic melanoma patients
according to the median value of
tumor CD3eCD56e cells retained in
the Cox multivariate model in tumor
analyses. Likelihood ratio tests from
Cox regression modeling are used to
assess the prognostic value for the
marker with and without accounting
for metastatic lymph node (mLN)
invasion status (0e3 vs >3).
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1000after log transformation. Dispersion was allowed to differ between
groups, and contrasts of interest were back-transformed and presented
as ratios. Wilcoxon signed-rank test was applied to assess differences
in concentration between matching pairs of blood leukocytes and
tumor-infiltrated cells samples. OS and progression-free survival (PFS)
determined from the date of sampling were used as the primary
endpoints. Survival curves were estimated by the Kaplan-Meier
product-limit method. Survival distributions were compared by Firth
penalized-likelihood Cox regression after stratifying for BRAF status,
gender, number of mLNs, and disease stage. Flow cytometric pa-
rameterswere converted to z-scores before computing the correlation
matrices. Unless stated, P-values are two sided, and 95% confidence
intervals for the statistic of interest are reported and were not adjusted
for false discovery rate.
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